Skip to main content
Contact Us
Subscribe
E-Edition
41°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Paxmedica Inc
(NQ:
PXMD
)
0.5100
-0.0250 (-4.67%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Mar 28, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Paxmedica Inc
< Previous
1
2
3
Next >
PaxMedica Inc. (NASDAQ: PXMD) Developing Pipeline to Address Unmet Needs in Autism Spectrum Disorder via Suramin Sodium
March 21, 2024
Via
Investor Brand Network
BioMedNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD) on Promising Path to Meet Medical Needs of ASD Patients
March 20, 2024
Via
Investor Brand Network
Exposures
Product Safety
BioMedNewsBreaks – PaxMedica Inc. (NASDAQ: PXMD) Shares Vision, Innovations in ASD Treatments in Updated Company Presentation
March 13, 2024
Via
Investor Brand Network
Rising Cases of Autism in UK Raise Concerns
March 08, 2024
Via
Investor Brand Network
PaxMedica Releases Fireside Chat Video with CEO Howard Weisman
December 06, 2023
Via
ACCESSWIRE
PaxMedica Updated Company Presentation Highlighting Innovations in Autism Spectrum Disorder Treatments
March 13, 2024
From
PaxMedica, Inc.
Via
GlobeNewswire
PaxMedica Inc. (NASDAQ: PXMD) Pursues Autism Treatment as Diagnostic App Shows Promise to Effective ASD Diagnosis
March 08, 2024
Via
Investor Brand Network
BioMedNewsBreaks – PaxMedica Inc. (NASDAQ: PXMD) Committed to Developing Groundbreaking Therapies, Transformative Solutions
March 01, 2024
Via
Investor Brand Network
PaxMedica Inc. (NASDAQ: PXMD) Developing Pipeline of Products to Address Prevalence and Unmet Medical Needs of Autism Spectrum Disorder
February 20, 2024
Via
Investor Brand Network
Study Links Microbiome Composition to Autism Spectrum Disorder
February 16, 2024
Via
Investor Brand Network
New Study Challenges Perception of Males Being More Susceptible to Autism
February 02, 2024
Via
Investor Brand Network
BioMedNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD) Dedicated to Enhancing Quality of Life for Individuals Living with ASD
January 26, 2024
Via
Investor Brand Network
Study Suggests Pediatric Autism Could Be Linked to Umbilical Cord Lipid Levels at Birth
January 19, 2024
Via
Investor Brand Network
InvestorBrandNetwork Highlights PaxMedica Inc.’s (NASDAQ: PXMD) Video Release on Transformative ASD Study
January 16, 2024
Via
Investor Brand Network
BioMedNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD) on Promising Path to Address Unmet ASD Needs
January 12, 2024
Via
Investor Brand Network
Israeli Study Offers Hope to Sleeping Sickness Patients
December 26, 2023
Via
Investor Brand Network
BioMedNewsBreaks – PaxMedica Inc. (NASDAQ: PXMD) Files 8-K Following Nasdaq Compliance Achievement
December 21, 2023
Via
Investor Brand Network
PaxMedica Inc. (NASDAQ: PXMD) Fireside Chat with CEO Howard Weisman Sheds Light on Company Achievements for ASD Therapy Pipeline
December 18, 2023
Via
Investor Brand Network
Chinese Researchers Notch Major Milestone in Developing Gene Editing System Against Autism
December 13, 2023
Via
Investor Brand Network
BioMedNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD) CEO Featured in Just-Released Fireside Chat Video
December 06, 2023
Via
Investor Brand Network
Exposures
Product Safety
PaxMedica Inc. (NASDAQ: PXMD) Completes Key Type-B FDA Meeting, Discussing Positive Results from PAX-HAT-301 Study
December 06, 2023
Via
Investor Brand Network
Exposures
Product Safety
PaxMedica Inc. (NASDAQ: PXMD) Closes Public Offering of Approximately $7 Million and Continues Pursuing ASD Pipeline
December 05, 2023
Via
Investor Brand Network
BioMedNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD) Featured in Recent H.C. Wainwright & Co. Research Report with ‘Buy’ Rating, $3 PT
December 04, 2023
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Study Shows Autistic People Have Lower Life Expectancy Than General Population
December 01, 2023
Via
Investor Brand Network
BioMedNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD) Closes on Public Offering Reaching Estimated $7M
November 27, 2023
Via
Investor Brand Network
PaxMedica Announces Closing of $7.0 Million Public Offering
November 22, 2023
Via
ACCESSWIRE
BioMedNewsBreaks – PaxMedica Inc. (NASDAQ: PXMD) Announces Pricing of $7M Public Offering
November 20, 2023
Via
Investor Brand Network
PaxMedica Announces Pricing of $7.0 Million Public Offering
November 20, 2023
Via
ACCESSWIRE
Study Examines Role of African Sleeping Sickness in Body Wasting
November 17, 2023
Via
Investor Brand Network
BioMedNewsBreaks — PaxMedica Inc. (NASDAQ: PXMD) News of FDA Type-B Meeting Shared in Syndicated Audio Broadcast
November 17, 2023
Via
Investor Brand Network
Exposures
Product Safety
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.